Sanara MedTech Inc. Announces an Update on the Execution of its Strategy

April 17, 2020 9:00 AM

FORT WORTH, TX / ACCESSWIRE / April 17, 2020 / Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara" or the "Company") (OTCQB:SMTI), a provider of surgical and chronic wound care products dedicated to improving patient outcomes, announced today an update on the execution of the Company's strategy. Record First Quarter 2020 Revenue and COVID-19 Impact For the first quarter of 2020, the Company...

Read more

Nanalysis to Present at the Planet MicroCap Virtual Showcase Investor Conference 2020

April 16, 2020 7:05 PM

CALGARY, ALBERTA, CANADA / ACCESSWIRE / April 16, 2020 / Nanalysis Scientific Corp. ("Nanalysis") (TSXV: NSCI)(OTCQX:NSCIF)(FRA: 1N1) is excited to announce that it will be participating in the Planet MicroCap Virtual Showcase 2020 on Wednesday, April 22. Mr. Sean Krakiwsky, CEO of Nanalysis will be hosting an investor presentation, answering questions from investors, participating in one-on-one investor calls, and...

Read more

Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer

April 16, 2020 12:20 PM

PARIS, FRANCE / ACCESSWIRE / April 16, 2020 / Pharnext SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence, today announced the appointment of Dr. David Horn Solomon as Chief Executive Officer of Pharnext, effective immediately. Dr. Solomon will also be proposed to join the Board of Directors at...

Read more

Tetra Receives its 4th FDA Orphan Drug Designation

April 16, 2020 8:00 AM

Tetra's PPP004 cannabinoid drug receives Orphan Drug Designation for the Treatment of Epidermolysis Bullosa OTTAWA / ACCESSWIRE / April 16, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP);(OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for its cannabinoid PPP004...

Read more

Analytical Validation of Cofactor Genomics' Immune Profiling Assay Published in Journal of Molecular Diagnostics

April 16, 2020 8:00 AM

Paper is first peer-reviewed publication of ImmunoPrism performance SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2020 / Today, Cofactor Genomics announced the peer-reviewed publication of an analytical validation study demonstrating the performance of its novel RNA-based immune profiling assay, ImmunoPrism®, in the April 2020 issue of the Journal of Molecular Diagnostics. The paper is the first public disclosure of the company's...

Read more

Xenetic Biosciences, Inc. to Present at the April 2020 Virtual Investor Summit

April 15, 2020 8:35 AM

Presentation with live audio webcast on Wednesday, April 22 at 11:30 AM ET, immediately followed by an interactive Q&A session FRAMINGHAM, MA / ACCESSWIRE / April 15, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens,...

Read more

Tetra Receives FDA Orphan Drug Designation for its Ophthalmic Clinical Program

April 15, 2020 8:00 AM

Tetra's PPP003 cannabinoid drug receives Orphan Drug Designation for the Prevention of Proliferative Vitreoretinopathy OTTAWA / ACCESSWIRE / April 15, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that it has received U.S. Food and Drug Administration (FDA) Orphan Drug Designation for...

Read more

Afecta Pharmaceuticals Joins Battle Against COVID-19

April 14, 2020 8:00 AM

IRVINE, CA / ACCESSWIRE / April 14, 2020 / Afecta Pharmaceuticals, a company focused on developing drugs that modulate the immune system announced that it has been invited to submit two of its lead drug candidates to the National Institute of Health to be evaluated for initiation of pre-clinical and potential clinical testing for treatment of 2019 novel Coronavirus (2019-nCoV). The compounds were identified using PharmetRx®, Afecta's...

Read more

Tetra BioPharma Confirms QIXLEEF Clinical Site Receives Renewal of DEA Schedule 1 License

April 14, 2020 8:00 AM

DEA Renews Schedule 1 License for Scottsdale Research Institute (Plenitude clinical site) OTTAWA / ACCESSWIRE / April 14, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX-V:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, is pleased to announce that Dr. Sue Sisley's Scottsdale Research Institute received the renewal of its Schedule 1 license from the US Drug...

Read more

Apollo Endosurgery Announces Completion of the US Post-Approval Study for the Orbera(R) Intragastric Balloon System

April 13, 2020 9:00 AM

AUSTIN, TX / ACCESSWIRE / April 13, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures announced today that the US Food and Drug Administration (FDA) has completed the review of the final Post-Approval Study (PAS) Report for the Orbera Intragastric Balloon System and accepted that all post-approval study requirements have been...

Read more

NascentBiotech's Independent Consultants Have Begun Research on Pribumumab as a Potential Therapeutic Agent Against (Coronavirus) Covid-19

April 7, 2020 4:35 PM

SAN DIEGO, CA / ACCESSWIRE / April 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), today announced that two independent consultants retained by the Company have begun preliminary research on a possible treatment for patients infected with the Coronavirus. An article in The Journal of Biological Medicine (Yu et al. Journal of Biomedical Science (2016) 23:14 DOI 10.1186/s12929-016-0234-7) specifically mentioned cell surface vimentin as a potential...

Read more

Informa PLC - Skipta Launches COVID-19 Forum & Lecture Series

April 6, 2020 12:45 PM

Skipta Launches COVID-19 Focus Area And Lecture Series For Healthcare Practitioners Forum for Coronavirus Information Sharing Will Utilize Pharma Intelligence Product Insights and Skipta's Vast Network of Healthcare Professionals NEW YORK, NY / ACCESSWIRE / April 6, 2020 / Skipta, the leading social network of specialized online medical communities for verified healthcare professionals including Oncology Nation, Doctor Unite, and...

Read more

HemaGenetics Technologies Applies Temporary Exemption (Group A) from Certain Corporate Finance Requirements under BC Instrument 51-515

April 6, 2020 9:00 AM

VANCOUVER, BC / ACCESSWIRE / April 6, 2020 / HemaGenetics Technologies Corp. (the "Company"), due to ongoing non-essential business shut down for COVID-19 measures taken by the Province of British Columbia, is exempt from Group A filings and delaying its annual financial statements release and filing on SEDAR as required under section 4.2 of NI 51-102 until June 1, 2020. As required under section 10 of BC Instrument 51-515, the...

Read more

GB Sciences Completes and Achieves Statistical Significance in Preclinical Study of Its Proprietary Parkinson's Disease Cannabinoid Formulations and Begins Mechanism of Action Study With the National Research Council of Canada

April 6, 2020 9:00 AM

LAS VEGAS / ACCESSWIRE / April 6, 2020 / GB Sciences, Inc. (OTCQB:GBLX), is pleased to announce that the company's Canadian entity, GBS Global Biopharma, Inc. (GBS), signed an Amendment to their Agreement with the National Research Council of Canada (NRC). The NRC has demonstrated that the company's PD formulations were able to reduce behavioral changes associated with the loss of dopamine-producing neurons, which underlies the...

Read more

American CryoStem to Develop ATCELL(TM) Clinical Study for Duchene Muscular Dystrophy with RACEMD

April 2, 2020 7:40 AM

EATONTOWN, NJ / ACCESSWIRE / April 2, 2020 / American CryoStem Corporation (OTC PINK:CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has that it has entered into a license and collaboration agreement to apply American CryoStem technologies for the development therapy in Duchenne...

Read more

Memgen Announces Addition to Board of Directors

April 2, 2020 6:00 AM

HOUSTON / ACCESSWIRE / April 2, 2020 / ​Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that Christopher Pagano has joined the company's Board of Directors. "I am delighted to join the board of Memgen at this exciting time in the company's development," noted Mr. Pagano. "Memgen is exploiting leading-edge science to develop novel and effective treatments for cancer...

Read more

Mota Raises $1.7 Million in Private Placement

April 1, 2020 3:00 AM

VANCOUVER, BC / ACCESSWIRE / April 1, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTCPINK:PEMTF) (the "Company") is pleased to announce that it has completed an offering (the "Offering") of 6,142,859 units (each, a "Unit") by way of non-brokered private placement at a price of $0.28 per Unit for gross proceeds of $1,720,000. Each Unit consists of one common share of the Company, and one common share purchase...

Read more

Angle PLC Announces COVID-19 BUSINESS IMPACT UPDATE

March 31, 2020 2:00 AM

GUILDFORD, SURREY / ACCESSWIRE / March 31, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update in relation to the impact of the Coronavirus (COVID-19) pandemic on its business. ANGLE's operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. We take the health, safety and wellbeing of our staff, blood donors...

Read more

Dyadic Reports 2019 Year End Results and Recent Developments

March 30, 2020 4:00 PM

New research license agreement with WuXi Biologics, a leading global CDMOTwo new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health companySix funded research collaborations and one expanded collaboration signed in 2019Expanded strategic R&D relationships to assist in the development of COVID-19 vaccine and antibodiesExpanded internal product...

Read more

ZIVO Bioscience Appoints Industry Veterans To Join Senior Management Team

March 30, 2020 11:20 AM

KEEGO HARBOR, MI / ACCESSWIRE / March 30, 2020 / ZIVO Bioscience, Inc. (OTCQB:ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal cultures, is pleased to announce today the addition of Christine O'Neil and Dr. David Lafond to its leadership team. Christine and Dave bring to the organization executive-level experience in the food, supplement, and pet food industry...

Read more